REG - IXICO plc - Non-Executive Director Appointment

IXICOAnnouncement

21/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220121:nRSU1566Za&default-theme=true

RNS Number : 1566Z  IXICO plc  21 January 2022

IXICO plc

("IXICO" or the "Company")

 

Non-Executive Director Appointment

 

IXICO plc (AIM: IXI) ('IXICO' or the 'Company'), the data analytics company
delivering insights in neuroscience, is pleased to announce the appointment of
Kate Rogers as a Non-Executive Director and Chair of the Audit Committee with
effect from 21 January 2022.

 

John Bradshaw, who has served as a non-executive director and Chair of the
Audit Committee since October 2013, has informed the Board of his intention to
retire owing to his length of service on the IXICO Board with effect from 30
April 2022. His responsibilities as IXICO's Chair of the Audit Committee will
be assumed by Kate Rogers with immediate effect.

 

Kate is currently leading the transformation of Glaxo SmithKline's global
finance organisation having previously worked as CFO for Laboratoire Glaxo
SmithKline SaS (GSK France) as well as other senior finance roles within GSK.
Kate holds a Bachelor of Science degree in Engineering from Oxford University
and qualified as a Chartered Management Accountant in 1999.

 

Charles Spicer, Chair of the Board said: "Personally, and on behalf of the
Board, I would like to thank John for the outstanding contribution he has made
to IXICO over the last nine years. His support for the Company and wise advice
to us all has been invaluable. We wish him well. Separately, we are delighted
to welcome Kate to IXICO and look forward to benefitting from her broad and
deep experience of both the pharmaceutical sector and international finance."

 

Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Katherine Jane
Rogers (previously Wall) (age 55) has held the following directorships or
partnerships in the past five years:

 

 Current  Previous
 None     Laboratoire Glaxosmithkline SAS

          Viiv Healthcare SAS

Ms Rogers does not currently hold any shares in the Company.

There is no further information required to be disclosed in respect of the
above appointment pursuant to Rule 17 and Schedule 2 (g) of the AIM Rules for
Companies.

 

For further information please contact:

 

 IXICO plc                                             +44 (0)20 3763 7498
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)              +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd   Tel: 020 7933 8780 or IXICO@walbrookpr.com
 Paul McManus / Alice Woodings       Mob: 07980 541 893 / 07407 804 654

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to
transform the progression of our biopharmaceutical clients' neurological
therapeutic pipelines through the application of novel imaging and digital
biomarkers.

 

IXICO's data analytics services are used by the global biopharmaceutical
industry to interpret data from brain scans and digital biosensors to enable
better trial design, site qualification, patient selection and clinical
outcomes. We provide technology-enabled services across all phases of clinical
evaluation. Our integrated digital platform provides a scalable and secure
infrastructure for the capture and analysis of regulatory compliant clinical
data to enable clients to make rapid, better informed decisions. IXICO is also
collaborating with partners to develop new analytical techniques and companion
digital health products targeted at improving patient outcomes.

 

More information is available on www.IXICO.com (http://www.IXICO.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASESFWSEESELF